

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
``09/728,422	11/30/2000	Y. Tom Tang	21272-029CIP2F	3265	
7:	590 10/22/2002				
Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.			EXAMINER		
			SOUAYA, JEHANNE E		
One Financial Center Boston, MA 02111		ART UNIT	PAPER NUMBER		
			1634	1634	
			DATE MAILED: 10/22/2002 43		

Please find below and/or attached an Office communication concerning this application or proceeding.

!

Application No. 09/728,422 Applicant(s)

Examiner

Art Unit



Office Action Summary 1634 Jehanne Souaya -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE _____1 ___ MONTH(S) FROM Period for Reply - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - , and to reply within the set of extended period for reply will, by statute, cause the application, to become Application (55 0.3.0. \$ 195).

- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1) X Responsive to communication(s) filed on Aug 5, 2002 Status 2b) This action is non-final. 3)
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is 2a) This action is FINAL. closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. 4) X Claim(s) 1-9 and 22-26 is/are pending in the application. Disposition of Claims 4a) Of the above, claim(s) ______ is/are withdrawn from consideration. 5) Claim(s) ______is/are allowed. 6) Claim(s) ______is/are rejected. ____ is/are objected to. 8) X Claims 1-9 and 22-26 are subject to restriction and/or election requirement. **Application Papers** 9) \square The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on ______ is/are a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on ______ is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Priority under 35 U.S.C. §§ 119 and 120 a) □ All b) □ Some* c) □ None of: 1. \square Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. _ 3.
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) \square The translation of the foreign language provisional application has been received. 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 4) Interview Summary (PTO-413) Paper No(s). Attachment(s) 5) Notice of Informal Patent Application (PTO-152) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Application/Control Number: 09/728,422 Page 2

Art Unit: 1634

DETAILED ACTION

Applicants election of SEQ ID NO 4 is noted. Applicants also indicate that the invention of Group I, claims 1-9 and 22-26 has been elected, however, the previous restriction requirement set forth claims 1-9 in Group I and claims 22-26 in Group VIII. A new restriction requirement is set forth below with regard to the claims pending, claims 1-9 and 22-26, it is noted however, that the new restriction requirement places claim 22 in Group I.

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-9 and 22, drawn to a polynucleotide, vectors and host cells comprising such, classified in class 536, subclass 23.1, class 435, subclass 320.1, and class 435, subclass 252.1, respectively.
 - II. Claims 23-26, drawn to a nucleic acid array, classified in class 435, subclass 287.2.
- 2. The inventions are distinct, each from the other because of the following reasons:

 The inventions of groups I and II are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because 1) the utility of a polynucleotide array does not necessarily depend on the utility

Application/Control Number: 09/728,422 Page 3

Art Unit: 1634

of each separate polynucleotide in the array, and 2) the polynucleotide array of Group II can be used in a method to identify differential expression of many different genes. The subcombination has separate utility such as the distinct polynucleotides of Group I can be used in recombinant methods to express proteins.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 09/728,422 Page 4

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703)308-6565. The examiner can normally be reached Monday-Friday from 9:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya

Patent examiner

Art Unit 1634

Oct 1, 2002